NEW PUBLICATION: Dermatology and Therapy published one-year results from ADvocate 1 & 2 of patients with moderate-to-severe atopic dermatitis treated with anti-IL-13 therapy, exploring patient’s stability of response. View full publication here: https://e.lilly/3yZELJ4
Lilly Medical US’ Post
More Relevant Posts
-
NEW PUBLICATION: Dermatology and Therapy published new study results of anti-IL-13 therapy from ADvocate 1 & 2, exploring stability of itch and skin responses at 52 weeks in patients with moderate-to-severe atopic dermatitis. View full publication here: https://e.lilly/3yBlyxu #AtopicDermatitis
To view or add a comment, sign in
-
New Publication in Dermatology and Therapy: The analysis of an IL-13 inhibitor across EASI body regions and clinical signs of Atopic Dermatitis, results from ADvocate 1 & ADvocate 2 trials. View the full publication here: https://e.lilly/4ayAaKR
To view or add a comment, sign in
-
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment : In this Dermatology Times article, listen to Christopher Bunick, MD, PhD, as he delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis. https://lnkd.in/gsDAMw86
To view or add a comment, sign in
-
Want to learn more about our AtopicDermatitis registry. Let’s schedule a meeting and discuss how we can support your dermatology development initiatives. #rwe #rwd #registry #atopicdermatitis
Now available online American Academy of Dermatology #JAAD: our co-authored research paper. It describes the demographic, clinical, and treatment characteristics among CorEvitas #AtopicDermatitis (AD) Registry patients in the first 2.5 years after inception and stratified by current systemic therapy use. https://hubs.la/Q02rbhvB0 #RWE #RWD #diseaseregistry
To view or add a comment, sign in
-
I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase
To view or add a comment, sign in
-
Most viewed in the last 7 days from JAMA Dermatology: What is the clinical effectiveness of dupilumab for long-term use in patients with atopic dermatitis, and what are reasons to discontinue dupilumab treatment? https://ja.ma/4fPcky7
To view or add a comment, sign in
-
Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024
To view or add a comment, sign in
-
Lawrence Eichenfield, M.D., discusses studies from the 2024 American Academy of Dermatology Annual Meeting that have significant implications for the management of atopic dermatitis (AD). Watch this K-Cast episode to learn more about key insights on AD from #AAD2024 https://bit.ly/3V8OQvC #AtopicDermatitis #ManagedCare https://bit.ly/3V8OQvC
To view or add a comment, sign in
-
Lots of exciting developments in #psoriasis #psoriaticarthritis #lupus to follow. I guess that's why #venturecapital investing $250M+ here. #clinicaltrials #arthritis #medicine #heathcare
Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024
To view or add a comment, sign in
-
Dive into the latest issue of Practical Dermatology for insightful coverage of the latest in dermatology research, practice management, products, best practices, meeting coverage, and more. Only at practicaldermatology.com.
To view or add a comment, sign in
17,195 followers